Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status

Performance of the new CE-IVD-marked HercepTest™ mAb pharmDx (Dako Omnis) assay (HercepTest (mAb)) was compared against the PATHWAY® anti-HER-2/neu (4B5) (PATHWAY 4B5) assay using 119 pre-selected breast cancer samples covering the entire range of HER2 immunohistochemistry (IHC) expression scores (0...

Descripción completa

Detalles Bibliográficos
Autores principales: Rüschoff, Josef, Friedrich, Michael, Nagelmeier, Iris, Kirchner, Matthias, Andresen, Lena M., Salomon, Karin, Portier, Bryce, Sredni, Simone T., Schildhaus, Hans Ulrich, Jasani, Bharat, Grzelinski, Marius, Viale, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636083/
https://www.ncbi.nlm.nih.gov/pubmed/35970977
http://dx.doi.org/10.1007/s00428-022-03378-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636083/
https://www.ncbi.nlm.nih.gov/pubmed/35970977
http://dx.doi.org/10.1007/s00428-022-03378-5

Ejemplares similares